Although expected to operate independently of cancer site and normal tissue type, the γ-H2AX assay’s ability to predict late radiation toxicity via the γ-FDR metric has not yet been examined in patient groups other than those with prostate cancer. The gene discussed is H2AX; the disease is prostate cancer.